1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
Appoints Anne Prener to its Board of Directors
Keros Therapeutics, Inc. 2026 Annual Meeting Results and Proposals Voted
Announces Participation at Goldman Sachs 47th Annual Global Healthcare Conference
Earnings Release
Annual Report to Security Holders
Presents Additional Clinical Data from Its Rinvatercept Program at the 2026 MDA Clinical & Scientific Conference
Investor Presentation
Financial Results, Press Release
Q1
FY 2025
Q3
Q2
FY 2023
Registration Statement for Securities to be Offered to Employees
SC TO-I
Tender Offer Statement by Issuer
Registration of Securities
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Notice of Proposed Sale of Securities
Amended Tender Offer Statement by Issuer